Zydus Lifesciences Limited
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Business Segments:
1) US Formulations (51% in Q1 FY25 vs 38% in FY22): The company distributes over 200 generic products in the U.S. market, holding leadership positions in more than 20% of its product families and ranking among the top three in approximately 60% of its products.
2) India Business (37% in Q1 FY25 vs 45% in FY22): The segment is split into:
a) Formulations (23% in Q1 FY25 vs 32% in FY22)
b) Consumer Wellness (14% in Q1 FY25 vs 13% in FY22):
3) International Markets Formulations (9% in Q1 FY25 vs 10% in FY22):
4) API (2% in Q1 FY25 vs 4% in FY22):
5) Alliances & Others (1% in Q1 FY25 vs 3% in FY22)
Shareholding Pattern (December 2025)
Financial Summary:
| Particular | Mar-21 | Mar-22 | Mar-23 | Mar-24 | Mar-25 |
| Sales – | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 |
| Sales Growth % | 5.96% | 1.08% | 12.92% | 13.40% | 18.90% |
| Expenses + | 11,758 | 11,923 | 13,378 | 14,163 | 16,183 |
| Operating Profit | 3,344 | 3,342 | 3,860 | 5,384 | 7,058 |
| OPM % | 22% | 22% | 22% | 28% | 30% |
| Net Profit + | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 |
| EPS in Rs | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 |
| Dividend Payout % | 17% | 6% | 31% | 8% | 24% |
Synopsis of Financials:
Consolidated revenue: ₹68.6 bn (+30% YoY).
EBITDA: ₹18.2 bn (+31% YoY); margin 26.5% (+20 bps YoY). 9M FY26 EBITDA margin: 30.3%
Adjusted net profit: ₹11.1 bn (+9% YoY)
Final Outlook:
Summary:
Zydus Lifesciences Ltd. is a fundamentally strong pharmaceutical company showing consistent revenue growth and improving profitability, driven mainly by its expanding US generics business and strong product portfolio. The company has delivered solid sales growth and margin expansion over the years, with recent quarters reflecting robust momentum.
Key Highlights:
1. Strong Revenue Growth
- Sales increased from ₹15,102 Cr (FY21) → ₹23,242 Cr (FY25)
- Consistent growth, especially ~19% in FY25
- Q3 FY26 revenue grew 30% YoY → very strong momentum
2.Improving Profitability:
- Operating margins improved from 22% → 30%
- EBITDA margin remains strong (~26–30%)
- Profit growth is stable, but slightly volatile in some years
Overall Analysis:
- Company is fundamentally strong
- Growth is visible and consistent
- Profitability is improving
Conclusion:
Zydus Lifesciences is a strong pharma company with good growth potential. Zydus Lifesciences presents a balanced investment case with strong growth potential supported by its expanding global presence, improving margins, and focus on the high-value US market. However, near-term challenges such as profit volatility, increased debt from acquisitions, and margin fluctuations may limit immediate upside. Therefore, while the company remains a solid long-term player in the pharmaceutical sector
